文献リスト

1) Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960; 17: 260-71

2) Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005; 353: 1591-603

3) Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol. 2008; 9(2-3): 147-57

4) López-Ríos F, Illei PB, Rusch V, et al. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet. 2004; 364: 1157-66

5) Carbone M, Emri S, Dogan AU, et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer. 2007; 7: 147-54

6) Hodgson JT, Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg. 2000; 44(8): 565-601

7) Miserocchi G, Sancini G, Mantegazza F, et al. Translocation pathways for inhaled asbestos fibers. Environ Health. 2008; 7: 4

8) Donaldson K, Murphy FA, Duffin R, et al. Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma. Part Fibre Toxicol. 2010; 7: 5

9) Müller KM, Schmitz I, Konstantinidis K. Black spots of the parietal pleura: morphology and formal pathogenesis. Respiration. 2002; 69: 261-7

10) 高田礼子. アスベストによる中皮腫発がんの分子機構. 医学のあゆみ. 2006; 11-12: 817-20

11) Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005; 366: 397-408

12) Kamp DW. Asbestos-induced lung diseases: an update. Transl Res. 2009; 153: 143-52

13) Hesterberg TW, Barrett JC. Induction by asbestos fibers of anaphase abnormalities: mechanism for aneuploidy induction and possibly carcinogenesis. Carcinogenesis. 1985; 6: 473-5

14) Shukla A, Gulumian M, Hei TK, et al. Multiple roles of oxidants in the pathogenesis of asbestos-induced diseases. Free Radic Biol Med. 2003; 34: 1117-29

15) Jiang L, Nagai H, Ohara H, et al. Characteristics and modifying factors of asbestos-induced oxidative DNA damage. Cancer Sci. 2008; 99: 2142-51

16) Msiska Z, Pacurari M, Mishra A, et al. DNA double-strand breaks by asbestos, silica, and titanium dioxide: possible biomarker of carcinogenic potential？ Am J Respir Cell Mol Biol. 2010; 43: 210-9

17) Murthy S, Adamcakova-Dodd A, Perry SS, et al. Modulation of reactive oxygen species by Racl or catalase prevents asbestos-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2009; 297: L846-55

18) Pociask DA, Sime PJ, Brody AR. Asbestos-derived reactive oxygen species activate TGF-beta1. Lab Invest. 2004; 84: 1013-23

19) Ghio A, Tan RJ, Ghio K, et al. Iron accumulation and expression of iron-related proteins following murine exposure to crocidolite. J Environ Pathol Toxicol Oncol. 2009; 28: 153-62

20) Ghio AJ, Stonehuerner J, Richards J, et al. Iron homeostasis in the lung following asbestos exposure. Antioxid Redox Signal. 2008; 10: 371-7

21) Aung W, Hasegawa S, Furukawa T, et al. Potential role of ferritin heavy chain in oxidative stress and apoptosis in human mesothelial and mesothelioma cells: implications for asbestos-induced oncogenesis. Carcinogenesis. 2007; 28: 2047-52

22) Gao F, Koenitzer JR, Tobolewski JM, et al. Extracellular superoxide dismutase inhibits inflammation by preventing oxidative fragmentation of hyaluronan. J Biol Chem. 2008; 283: 6058-66

23) Kliment CR, Englert JM, Gochuico BR, et al. Oxidative stress alters syndecan-1 distribution in lungs with pulmonary fibrosis. J Biol Chem. 2009; 284: 3537-45

24) Heintz NH, Janssen-Heininger YM, Mossman BT. Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol. 2010; 42: 133-9

25) Jaurand MC, Fleury-Feith J. Pathogenesis of malignant pleural mesothelioma. Respirology. 2005; 10: 2-8

26) Heintz NH, Janssen YM, Mossman BT. Persistent induction of c-fos and c-jun expression by asbestos. Proc Natl Acad Sci U S A. 1993; 90: 3299-303

27) Manning CB, Cummins AB, Jung MW, et al. A mutant epidermal growth factor receptor targeted to lung epithelium inhibits asbestos-induced proliferation and proto-oncogene expression. Cancer Res. 2002; 62: 4169-75

28) Ramos-Nino ME, Timblin CR, Mossman BT. Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression. Cancer Res. 2002; 62: 6065-9

29) Scapoli L, Ramos-Nino ME, Martinelli M, et al. Src-dependent ERK5 and Src/EGFR-dependent ERK1/2 activation is required for cell proliferation by asbestos. Oncogene. 2004; 23: 805-13

30) Yang H, Bocchetta M, Kroczynska B, et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappa B-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci U S A. 2006; 103: 10397-402

31) Janssen YM, Barchowsky A, Treadwell M, et al. Asbestos induces nuclear factor kappa B (NF-kappa B) DNA-binding activity and NF-kappa B-dependent gene expression in tracheal epithelial cells. Proc Natl Acad Sci U S A. 1995; 92: 8458-62

32) Altomare DA, You H, Xiao GH, et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene. 2005; 24: 6080-9

33) Dostert C, Pétrilli V, Van Bruggen R, et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008; 320: 674-7

34) Cassel SL, Eisenbarth SC, Iyer SS, et al. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci U S A. 2008; 105: 9035-40

35) Liu G, Beri R, Mueller A, et al. Molecular mechanisms of asbestos-induced lung epithelial cell apoptosis. Chem Biol Interact. 2010. In press

36) Goldberg JL, Zanella CL, Janssen YM, et al. Novel cell imaging techniques show induction of apoptosis and proliferation in mesothelial cells by asbestos. Am J Respir Cell Mol Biol. 1997; 17: 265-71

37) Panduri V, Weitzman SA, Chandel N, et al. The mitochondria-regulated death pathway mediates asbestos-induced alveolar epithelial cell apoptosis. Am J Respir Cell Mol Biol. 2003; 28: 241-8

38) Shukla A, Stern M, Lounsbury KM, et al. Asbestos-induced apoptosis is protein kinase C delta-dependent. Am J Respir Cell Mol Biol. 2003; 29: 198-205

39) Panduri V, Surapureddi S, Soberanes S, et al. P53 mediates amosite asbestos-induced alveolar epithelial cell mitochondria-regulated apoptosis. Am J Respir Cell Mol Biol. 2006; 34: 443-52

40) Buder-Hoffmann SA, Shukla A, Barrett TF, et al. A protein kinase C delta-dependent protein kinase D pathway modulates ERK1/2 and JNK1/2 phosphorylation and Bim-associated apoptosis by asbestos. Am J Pathol. 2009; 174: 449-59

41) Barlow CA, Barrett TF, Shukla A, et al. Asbestos-mediated CREB phosphorylation is regulated by protein kinase A and extracellular signal-regulated kinases 1/2. Am J Physiol Lung Cell Mol Physiol. 2007; 292: L1361-9

42) Panduri V, Liu G, Surapureddi S, et al. Role of mitochondrial hOGG1 and aconitase in oxidant-induced lung epithelial cell apoptosis. Free Radic Biol Med. 2009; 47: 750-9

43) Yang H, Rivera Z, Jube S, et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A. 2010; 107: 12611-6

44) Nakamura E, Makishima A, Hagino K, et al. Accumulation of radium in ferruginous protein bodies formed in lung tissue: association of resulting radiation hotspots with malignant mesothelioma and other malignancies. Proc Jpn Acad Ser B Phys Biol Sci. 2009; 85: 229-39

45) Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol. 2002; 29: 2-17

46) Froom P, Lahat N, Kristal-Boneh E, et al. Circulating natural killer cells in retired asbestos cement workers. J Occup Environ Med. 2000; 42: 19-24

47) Nishimura Y, Miura Y, Maeda M, et al. Impairment in cytotoxicity and expression of NK cell- activating receptors on human NK cells following exposure to asbestos fibers. Int J Immunopathol Pharmacol. 2009; 22: 579-90

48) Sekido Y. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci. 2010; 101: 1-6

49) 植松和嗣. 中皮腫の分子解析. 日胸. 2006; 65: 606-16

50) Musti M, Kettunen E, Dragonieri S, et al. Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet Cytogenet. 2006; 170: 9-15

51) Altomare DA, Menges CW, Pei J, et al. Activated TNF-alpha/NF-kappa B signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice. Proc Natl Acad Sci U S A. 2009; 106: 3420-5

52) Cheng JQ, Lee WC, Klein MA, et al. Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosomes Cancer. 1999; 24: 238-42

53) Ivanova AV, Ivanov SV, Prudkin L, et al. Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. Mol Cancer. 2009; 8: 91

54) Gordon GJ, Rockwell GN, Jensen RV, et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol. 2005; 166: 1827-40

55) Taniguchi T, Karnan S, Fukui T, et al. Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci. 2007; 98: 438-46

56) Heintz NH, Janssen YM, Mossman BT. Persistent induction of c-fos and c-jun expression by asbestos. Proc Natl Acad Sci U S A. 1993; 90: 3299-303

57) Shukla A, MacPherson MB, Hillegass J, et al. Alterations in gene expression in human mesothelial cells correlate with mineral pathogenicity. Am J Respir Cell Mol Biol. 2009; 41: 114-23

58) Govindan R, Kratzke RA, Herndon JE, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005; 11: 2300-4

59) Mathy A, Baas P, Dalesio O, et al. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer. 2005; 50: 83-6

60) Kawaguchi K, Murakami H, Taniguchi T, et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis. 2009; 30: 1097-105

61) Sartore-Bianchi A, Gasparri F, Galvani A, et al. Bortezomib inhibits nuclear factor-kappa B dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res. 2007; 13: 5942-51

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp